The Drug Report

America stands at a crossroads in our battle against addiction, facing the deadliest drug crisis in our nation’s history. With over 100,000 overdose deaths annually, the devastation is undeniable—but so are the solutions. In this special episode, you’ll get an exclusive first look into Kevin’s groundbreaking new book, One Nation Under the Influence.

Kevin reveals how proven prevention strategies could slash regular drug use by two-t...

Drug policy in America is at a critical inflection point. Following a period dominated by extreme harm reduction approaches, we're witnessing a significant shift back toward accountability-based treatment models. This transformation comes as cities like San Francisco and states like Oregon roll back failed experiments that provided tools for addiction without addressing its root causes.

Dr. Kevin Sabet joins us fresh ...

The fentanyl crisis represents one of America's most pressing public health emergencies, one that has affected countless families and communities across the country. In this engaging episode with Dr. Robert Marbut, we explore the alarming statistics surrounding fentanyl's impact, which has become a leading cause of death, eclipsing even the toll from warfare. Dr. Marbut, a distinguished expert on homelessness and addictio...

High THC cannabis products are under intense scrutiny, and with good reason. Kevin Sabet, CEO of SAM Smart Approaches to Marijuana, joins us to dissect the cannabis industry's parallels with big tobacco, especially concerning unproven health claims and the relentless drive for profit. We examine a noteworthy New York Times article and question whether New York's $1 billion in cannabis sales is worth the potential cost to ...

Can relentless advocacy truly shape the future of marijuana legislation? Join us on the Drug Report podcast as we explore the recent triumph in New Hampshire, where the unwavering efforts of advocates have led Governor Kelly Ayotte to promise a veto on any future marijuana legalization attempts. This victory shines a light on the power of persistence in the ever-evolving landscape of drug policy. As we navigate through these pivota...

Could the defeat of Florida's marijuana legalization measure signal a turning tide in drug policy across America? Despite an avalanche of financial backing and celebrity endorsements, Florida's initiative fell short, leaving many to question the power dynamics at play. Join us as we unpack the surprising outcome, delving into the influential role of grassroots campaigns and bipartisan voices, such as the powerful advocacy...

Discover the complexities of today's drug policy landscape with insights from around the globe. We promise an enlightening journey as Kevin Sabat and I unpack the highlights from the recent Lisbon Addictions Conference. We bring you the latest updates and debates on harm reduction versus legalization, spotlighting data-driven discussions from regions like Oregon and British Columbia. As we shift focus to the United States, unc...

Is federal marijuana legalization truly a win for Black men, or are there hidden pitfalls? Join us as we take a hard look at Vice President Kamala Harris's proposal, focusing on its goal to dismantle systemic barriers and whether it achieves this when it poses new public health risks. With insightful commentary from Will Jones of SAM, we unravel the intricate dynamics between promising business opportunities and the risks of c...

Can marijuana regulation backfire on public health? Join us on the Drug Report podcast as we celebrate International Recovery Day and tackle this provocative question with insights from experts like Michael Botticelli and John Kelly. We'll share highlights from a global webinar focused on the mechanisms and societal support necessary for successful recovery. We'll also respond to Robert Gebeloff's Washington Post col...

Can the FDA really pull THC-infused edibles off the shelves? We'll take you inside a gripping congressional hearing where FDA Deputy Commissioner for Human Foods, James Jones, found himself in the hot seat, interrogated by Congresswoman Kathy McMorris-Rogers. Unravel the complexities of the Federal Food, Drug, and Cosmetic Act and understand the real-world implications of the Blumenauer Amendment, which ties the FDA's han...

Can a balanced approach to harm reduction and recovery really save lives? Join us in a thought-provoking conversation with Tom Wolf, a member of the Recovery community from San Francisco, offering a raw and unfiltered critique of today's drug policies. We scrutinize Vancouver's harm reduction model and its alarming overdose death rates, while Tom passionately argues for recovery-focused solutions in the face of new propos...

Can marijuana use really be costing businesses millions? In this episode of the Drug Report Podcast, we unpack a revealing study from the American Journal of Preventative Medicine that draws a stark connection between cannabis use disorder and rising workplace absenteeism. From the financial strain on employers to the ripple effects on the economy, we analyze the true cost of marijuana in the workplace. We also bring to light alarm...

This episode of the Drug Report podcast unpacks the FDA's recent decision to reject Lykos' psilocybin product intended for treating PTSD, a move that has sparked fierce debate. We also delve into the significant fallout for Lykos, from massive layoffs and leadership upheavals to the company's uncertain future. Plus, the tragic case of Matthew Perry is intertwined with broader concerns about the safety and efficacy of...

Can marijuana legalization really dismantle our overcrowded prisons? Find out in today's episode as we unravel the myths and misconceptions about marijuana possession and imprisonment. We begin by examining the widely held belief that legalizing marijuana will significantly reduce prison populations. Using President Biden's historic federal pardons as a case study, we expose the reality: no one was serving federal prison ...

What if the very strategies intended to reduce harm from drug use are actually endangering the very people they aim to protect? This episode of the Drug Report promises to tackle the complexities and controversies surrounding research into harm reduction in drug policy. With significant federal funding now backing harm reduction research, we stress the critical importance of reputable science in shaping effective policies. Hear our...

Join us as we take you through the gripping details of Philip Morris' latest move to build a "Zyn" nicotine pouch factory in Aurora, Colorado—their first U.S. factory in half a century. This episode kicks off with a bold discussion on my recent op-ed critiquing the economic incentives granted by the Aurora City Council and the uncritical media coverage of this development. We expose the alarming health risks tied to ...